Wednesday, September 23, 2026

PRA Health Sciences, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

PRA Health Sciences, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Tronox Limited Ordinary Shares

47.9% sales growth and 71.4% return on equity

Tronox Holdings plc operates as a vertically integrated manufacturer of TiO2 pigment in South and Central America, Europe, the Middle East, Africa, and the Asia Pacific.

Tronox Limited Ordinary Shares's sales growth this year is expected to be 17.9% and 4% for next year.

Year-on-year quarterly revenue growth grew by 13%, now sitting on 2.76B for the twelve trailing months.

Tronox Limited Ordinary Shares's sales growth for the next quarter is 47.9%. The company's growth estimates for the present quarter and the next is a negative 3.4% and 1366.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 71.4%.

Volatility

Tronox Limited Ordinary Shares's last day, last week, and last month's current volatility was 4.51%, 2.90%, and 2.86%, respectively.

Tronox Limited Ordinary Shares's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.88% (day), 4.91% (last week), and 4.68% (last month), respectively.

Tronox Limited Ordinary Shares's Stock Yearly Top and Bottom Value

Tronox Limited Ordinary Shares's stock is valued at $20.61 at 20:22 EST, below its 52-week high of $21.36 and way higher than its 52-week low of $4.66.

Tronox Limited Ordinary Shares's Moving Average

Tronox Limited Ordinary Shares's worth is way above its 50-day moving average of $18.38 and way higher than its 200-day moving average of $14.09.

3. Littelfuse, Inc.

59.1% sales growth and 8.37% return on equity

Littelfuse, Inc. manufactures and sells circuit protection, power control, and sensing products in the Asia-Pacific, the Americas, and Europe.

Littelfuse, Inc.'s sales growth this year is expected to be 19.5% and 6.6% for next year.

Year-on-year quarterly revenue growth grew by 18.4%, now sitting on 1.45B for the twelve trailing months.

Littelfuse, Inc.'s sales growth for the next quarter is 59.1%. The company's growth estimates for the current quarter and the next is 47.3% and 193%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.37%.

Volatility

Littelfuse, Inc.'s last day, last week, and last month's current volatility was 3.02%, 1.64%, and 1.37%, respectively.

Littelfuse, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.31% (day), 2.43% (last week), and 2.43% (last month), respectively.

Littelfuse, Inc.'s Stock Yearly Top and Bottom Value

Littelfuse, Inc.'s stock is valued at $275.94 at 20:22 EST, under its 52-week high of $287.92 and way higher than its 52-week low of $131.81.

Littelfuse, Inc.'s Moving Average

Littelfuse, Inc.'s value is above its 50-day moving average of $266.96 and way above its 200-day moving average of $248.15.

4. Alexion Pharmaceuticals, Inc.

12.9% sales growth and 5.26% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals, Inc.'s sales growth this year is expected to be 8% and 7.9% for next year.

Year-on-year quarterly revenue growth grew by 15%, now sitting on 6.07B for the twelve trailing months.

Alexion Pharmaceuticals, Inc.'s sales growth for the next quarter is 12.9%. The company's growth estimates for the ongoing quarter and the next is a negative 1.9% and 4.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.26%.

Volatility

Alexion Pharmaceuticals, Inc.'s last day, last week, and last month's current volatility was 0.44%, 0.76%, and 0.91%, respectively.

Alexion Pharmaceuticals, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.72% (day), 0.78% (last week), and 1.01% (last month), respectively.

Alexion Pharmaceuticals, Inc.'s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals, Inc.'s stock is valued at $166.92 at 20:22 EST, below its 52-week high of $167.77 and way above its 52-week low of $94.00.

Alexion Pharmaceuticals, Inc.'s Moving Average

Alexion Pharmaceuticals, Inc.'s worth is higher than its 50-day moving average of $152.93 and way above its 200-day moving average of $139.50.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com